10,099 Shares in Moderna, Inc. $MRNA Acquired by AXQ Capital LP

AXQ Capital LP purchased a new stake in shares of Moderna, Inc. (NASDAQ:MRNA) in the second quarter, according to its most recent disclosure with the SEC. The firm purchased 10,099 shares of the company’s stock, valued at approximately $279,000.

Several other hedge funds also recently modified their holdings of MRNA. Geode Capital Management LLC lifted its holdings in shares of Moderna by 19.1% in the second quarter. Geode Capital Management LLC now owns 8,877,280 shares of the company’s stock valued at $244,458,000 after buying an additional 1,420,690 shares during the period. Vanguard Group Inc. grew its holdings in Moderna by 3.2% during the second quarter. Vanguard Group Inc. now owns 41,708,705 shares of the company’s stock worth $1,150,743,000 after acquiring an additional 1,312,192 shares during the period. SHANDA ASSET MANAGEMENT HOLDINGS Ltd bought a new stake in Moderna in the first quarter worth about $28,350,000. Jacobs Levy Equity Management Inc. acquired a new stake in Moderna in the 1st quarter valued at about $28,308,000. Finally, Jump Financial LLC lifted its holdings in Moderna by 5,590.0% in the 1st quarter. Jump Financial LLC now owns 902,427 shares of the company’s stock valued at $25,584,000 after acquiring an additional 886,567 shares during the last quarter. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

MRNA has been the topic of several recent research reports. JPMorgan Chase & Co. lowered their price objective on shares of Moderna from $26.00 to $25.00 and set an “underweight” rating on the stock in a research note on Thursday, October 23rd. Morgan Stanley lifted their price target on shares of Moderna from $31.00 to $32.00 and gave the stock an “equal weight” rating in a research report on Friday, October 10th. Needham & Company LLC reaffirmed a “hold” rating on shares of Moderna in a report on Monday, October 20th. Bank of America reduced their price objective on Moderna from $24.00 to $21.00 and set an “underperform” rating for the company in a research note on Monday, November 10th. Finally, Berenberg Bank set a $28.00 target price on Moderna in a report on Monday, November 17th. Two investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and five have given a Sell rating to the stock. According to data from MarketBeat.com, Moderna presently has an average rating of “Reduce” and a consensus target price of $29.46.

Moderna Price Performance

NASDAQ:MRNA opened at $24.15 on Tuesday. The stock has a market cap of $9.44 billion, a PE ratio of -2.99 and a beta of 2.02. Moderna, Inc. has a fifty-two week low of $22.28 and a fifty-two week high of $48.92. The stock’s 50-day moving average is $25.88 and its two-hundred day moving average is $26.98.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings results on Thursday, November 6th. The company reported ($0.51) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.15) by $1.64. The business had revenue of $1.02 billion during the quarter, compared to analyst estimates of $893.29 million. Moderna had a negative net margin of 139.61% and a negative return on equity of 29.81%. The firm’s revenue was down 45.4% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.03 earnings per share. Moderna has set its FY 2025 guidance at EPS. On average, equities research analysts anticipate that Moderna, Inc. will post -9.61 earnings per share for the current year.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.